Go Sugahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Go Sugahara has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Meng Li
USC Libraries Bioinformatic Services of the University of Southern California, Los Angeles, CA 90033, USA
2 shared publications - Takeshi Saito
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
2 shared publications - Alexander Zambidis
Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA
1 shared publication - Anthoula Lazaris
Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, QC H3H 2R9, Canada
1 shared publication - Audrey Kapelanski-Lamoureux
Department of Anatomy and Cell Biology, McGill University, Quebec, QC H3A 0G4, Canada
1 shared publication - Bill Lam
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California (USC), Los Angeles, California, USA
1 shared publication
Latest Publications
- 12 June 2024
- Published by Elsevier in Metabolism
- Vol. 159, 155942
The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1
- 12 June 2024
- Published by Elsevier in Metabolism
- Vol. 159, 155942
The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1
- Open Access
- 8 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (9)
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Hepatitis delta virus (HDV), a satellite virus of HBV, is regarded as the most severe type of hepatitis virus because of the substantial morbidity and mortality. The IFN system is the first line of defense against viral infections and an essential element of antiviral immunity; however, the role of the hepatic IFN system in controlling HBV-HDV infection remains poorly understood. Herein, we showed that HDV infection of human hepatocytes induced a potent and persistent activation of the IFN system whereas HBV was inert in triggering hepatic antiviral response. Moreover, we demonstrated that HDV-induced constitutive activation of the hepatic IFN system resulted in a potent suppression of HBV while modestly inhibiting HDV. Thus, these pathogens are equipped with distinctive immunogenicity and varying sensitivity to the antiviral effectors of IFN, leading to the establishment of a paradoxical mode of viral interference wherein HDV, the superinfectant, outcompetes HBV, the primary pathogen. Furthermore, our study revealed that HDV-induced constitutive IFN system activation led to a state of IFN refractoriness, rendering therapeutic IFNs ineffective. The present study provides potentially novel insights into the role of the hepatic IFN system in regulating HBV-HDV infection dynamics and its therapeutic implications through elucidating the molecular basis underlying the inefficacy of IFN-based antiviral strategies against HBV-HDV infection.
- 8 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (9)
Open AccessPersistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Hepatitis delta virus (HDV), a satellite virus of HBV, is regarded as the most severe type of hepatitis virus because of the substantial morbidity and mortality. The IFN system is the first line of defense against viral infections and an essential element of antiviral immunity; however, the role of the hepatic IFN system in controlling HBV-HDV infection remains poorly understood. Herein, we showed that HDV infection of human hepatocytes induced a potent and persistent activation of the IFN system whereas HBV was inert in triggering hepatic antiviral response. Moreover, we demonstrated that HDV-induced constitutive activation of the hepatic IFN system resulted in a potent suppression of HBV while modestly inhibiting HDV. Thus, these pathogens are equipped with distinctive immunogenicity and varying sensitivity to the antiviral effectors of IFN, leading to the establishment of a paradoxical mode of viral interference wherein HDV, the superinfectant, outcompetes HBV, the primary pathogen. Furthermore, our study revealed that HDV-induced constitutive IFN system activation led to a state of IFN refractoriness, rendering therapeutic IFNs ineffective. The present study provides potentially novel insights into the role of the hepatic IFN system in regulating HBV-HDV infection dynamics and its therapeutic implications through elucidating the molecular basis underlying the inefficacy of IFN-based antiviral strategies against HBV-HDV infection.